> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Expressions of Interest now invited for the London Region I AI Regulatory Sandbox.
- URL: https://med-techinsights.com/expressions-of-interest-now-invited-for-the-london-region-i-ai-regulatory-sandbox/
- Published: 2026-07-30T11:18:15.000Z
- Updated: 2026-10-22T08:02:49.000Z
- Description: Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications, signposts a new opportunity for those in the MedTech sector incorporating AI into their devices. AI medical device manufacturers and London-based NHS providers are being invi
- Author: Oliver Johnson
- Tags: Insights, Digital Health & AI, Policy & Regulation

###### [*Chris Whitehouse*](https://med-techinsights.com/tag/chris-whitehouse/)*, a political consultant and expert on medical technology policy and regulation at* [*Whitehouse Communications*](http://www.whitehousecomms.com/?ref=med-techinsights.com)*, signposts a new opportunity for those in the MedTech sector incorporating AI into their devices.*

---

AI medical device manufacturers and London-based NHS providers are [being invited](https://www.gov.uk/government/publications/london-region-i-mhra-regulatory-sandbox-call-for-expressions-of-interest/london-region-i-mhra-regulatory-sandbox-call-for-expressions-of-interest?ref=med-techinsights.com) to submit an Expression of Interest to participate in a programme to support the evaluation of AI-enabled medical devices in real-world NHS settings. Further information, including eligibility criteria and application details, is available in the [call for applications](https://www.gov.uk/government/publications/london-region-i-mhra-regulatory-sandbox-call-for-expressions-of-interest?ref=med-techinsights.com).

Earlier this year, medical device regulator, the [Medicines and Healthcare Devices Regulatory Agency](https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency?ref=med-techinsights.com) (MHRA) said that patients across London would benefit from faster access to innovative, AI‑powered healthcare technologies, as the agency in partnership with NHS England (London) and the London Health Innovation Networks (HINs), as it [announced](https://www.gov.uk/government/news/pioneering-ai-health-innovations-regulatory-sandbox-launched?utm%5Fmedium=email&utm%5Fcampaign=govuk-notifications-topic&utm%5Fsource=3ea6bbc3-04d2-41ef-98d3-d44f1d1cd712&utm%5Fcontent=immediately#full-publication-update-history) a new regulatory sandbox.

The initiative, known as London Region I, is intended to create a real-world environment to safely deploy AI-enabled medical devices while generating additional evidence of benefit across NHS settings, helping ensure patients can access new technologies earlier while maintaining the highest standards of safety.

By bringing together regulators, healthcare providers and innovators, the sandbox provides a controlled environment so cutting-edge technologies can be safely and securely deployed. The programme will support delivery of the [NHS 10 Year Health Plan](https://www.england.nhs.uk/long-term-plan/?ref=med-techinsights.com) by enabling faster adoption of technologies that improve patient outcomes, expand access to care, and reduce health inequalities.

Up to 10 AI medical device manufacturers will be selected to participate in the initial phase, working alongside NHS providers across London to deploy technologies in live clinical settings under MHRA oversight.

By enabling controlled, outcomes-based deployment, the sandbox aims to generate robust real-world evidence on safety and effectiveness while supporting a clearer, more predictable route to wider adoption.

The programme will support collaboration between providers and innovators, helping to match technologies with real system needs and enabling rapid, evidence-led deployment in practice.

*The Author used AI in preparing this article. Comments upon or questions about this article can be addressed to* [*chris.whitehouse@whitehousecomms.com*](mailto:chris.whitehouse@whitehousecomms.com)*.*